His Take/Her Take: Bruno

Worth the price of admission, or a waste of time? Brian McKechnie and Suzanne Ellis offer you their take on the latest movies hitting screens. Read their reviews every week, exclusively on CityNews.ca.

Let Brian and Suzanne know what you think of His Take/Her Take via email at brian.mckechnie@citynews.ca or suzanne.ellis@citynews.ca .

BRÜNO

Rated R
Cast: Sacha Baron Cohen
Directed by: Larry Charles
Official Site IMDb

When gay, Austrian fashion show host Brüno is fired from his television show he moves to the United States to attempt to become famous.

Brian’s Take

** out of 5 stars

About half an hour into the Brüno screening someone a few rows in front of me got up and yelled how much the movie sucked and walked out. Sadly, I think more people wanted to follow but didn’t with hopes it would get better, myself included.

I had high hopes and really wanted to like it. The trailers made me laugh and I thought it was fail-proof since I loved what Sacha Baron Cohen and director Larry Charles did with Borat . Unfortunately Brüno felt stale and made me ask: didn’t we see this movie in 2006 when it was called Borat?

Like Borat, Brüno is also a fish-out-of-water story. After he’s fired from his Austrian fashion television show (and his boyfriend leaves him) Brüno (Cohen) moves to Los Angeles with hopes to become a star. Along the way he adopts an African baby, joins the Army, tries to make a sex-tape with Ron Paul and exposes unsuspecting Americans as homophobes. Unlike Borat, it’s not that funny.

It’s too bad Cohen went this route instead of doing more original comedy. He’s a funny guy. His French Formula One character in Talladega Nights saved that movie for me. And seeing him in Tim Burton’s Sweeney Todd adaptation was refreshing. The problem with Brüno is Brüno. He gets annoying fast. Short bits with him on Da Ali G Show were much funnier than this film. And where Borat felt natural and real Brüno feels staged and forced.

There are some funny moments and I did laugh a few times. But most of the jokes you’ve already seen if you’ve watched the trailer. And the scenes that were added for pure shock value (Brüno being whipped by a woman at a swingers party when he won’t do the deed with her for example) always seem to go nowhere.

If you want to see Brüno stay home and rent Da Ali G Show instead. Or better yet watch Borat again. Both will give you better laughs for your money.


Suzanne’s Take

** out of 5 stars

Five minutes into Brüno , the latest film to revolve around a Sacha Baron Cohen character, I was reminded of Fashion Television’s short-lived feature The Husk Report .

For those who don’t remember, The Husk Report starred Scott Thompson of The Kids in the Hall as intrepid fashion reporter Danny Husk. Husk’s cheeky dispatches from the world of fashion were cutting, hilarious, and raw, bringing a welcome dose of tongue-in-cheek humour to a business that often takes itself far too seriously. Check it out here.

Similarly, gay Austrian TV host Brüno (Cohen) covers the fashion beat on his what’s hot/what’s not program, but unlike Husk he craves to be a part of the glamourous world, instead of trashing it. And though watching a Velcro-suit-clad Brüno fall on his face on the catwalk is undeniably funny, the rawness that made The Husk Report so funny and unexpected, and which I figured Brüno would have in spades, was largely absent.

That same rawness is part of what made Cohen’s last outing, the 2006 smash-hit Borat: Cultural Learnings of America for Make Benefit Glorious Nation of Kazakhstan , so effective. As Kazakh journalist Borat, Cohen put himself in ridiculous and sometimes perilous situations for the benefit of the film. As evidenced by the unwieldy title, the main target was America and the ultra-conservative Borat managed to elicit some incredibly dim-witted and ignorant comments from his interview subjects.

The formula is pretty much the same in Brüno, as the outspoken character stirs the pot with his words, and sees what bubbles up. After getting fired from his show and blacklisted in Austria, he moves to the U.S. in the hopes of becoming famous. When his initial attempts fail, he comes up with a number of get-famous-quick schemes, all of which end up pissing people off. He grills a purported terrorist in the Middle East in the hopes of becoming a hostage, attempts to seduce U.S. politician Ron Paul for a sex tape, and adopts an African baby (Hey, if Brangelina and Madonna are doing it…) in his quest for notoriety.

So much of Brüno felt scripted, even the parts that I’m guessing weren’t. For instance, in one scene the Austrian host is interviewing parents of toddlers for a photo shoot with the child he’s adopted. He asks the parents whether they’d put their children on diets, allow them near heavy machinery, etc., and the responses are predictably infuriating. Later, he makes out with his male assistant before an audience of homophobes, who respond by first throwing first their plastic cups and then their chairs. There are only so many ugly-American jokes you can take before you crave something else.

Though the characters Brüno and Borat couldn’t be more different, there’s a staleness in Cohen’s most recent effort, and a sense that we’ve seen this shtick before. And it was funnier three years ago, before Cohen himself was uber-famous.

There’s no denying Cohen is an incredibly gifted and clever comedian, and I give him enormous credit for putting himself in these situations for his art, but with Brüno the ends don’t justify the means.

 

Keep it Factual
Add CityNews Toronto as a trusted source on Google to see more local stories from us.

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

1h ago

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

1h ago

Most Watched Today